Table 2.
The clinical parameters of the dominant eyes or non-dominant eyes before and after the Implantable Collamer Lens (ICL) V4c implantation or Femtosecond Laser-Assisted Laser in Situ Keratomileusis (FS-LASIK).
| Characteristic | D- or nD-eye | Preoperative | 1-mon follow-up | 54-mon follow-up | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ICL V4c Group | FS-LASIK Group | P | ICL V4c Group | FS-LASIK Group | P | ICL V4c Group | FS-LASIK Group | P | ||
| UDVA (Logmar) | D-eye | NA | NA | NA | − 0.05 ± 0.07 | − 0.01 ± 0.06* | 0.417 | 0.13 ± 0.12▲ | 0.15 ± 0.26 | 0.865 |
| nD-eye | 0.05 ± 0.11 | 0.26 ± 0.21* | < 0.001 | 0.25 ± 0.21▲ | 0.67 ± 0.48▲ | < 0.001 | ||||
| Refraction sphere(D) | D-eye | − 10.60 ± 3.18 | − 6.94 ± 3.04 | 0.016 | 0.17 ± 0.34△ | 0 ± 0.28△* | 0.470 | − 0.33 ± 0.39△ | − 0.46 ± 0.66△* | 0.678 |
| nD-eye | − 11.50 ± 4.80 | − 8.54 ± 4.22 | 0.049 | − 0.17 ± 0.37△ | − 1.5 ± 0.96△* | < 0.001 | − 0.77 ± 0.67△▲ | − 1.98 ± 1.05△▲* | < 0.001 | |
| Refraction cylinder(D) | D-eye | − 1.63 ± 1.06 | − 0.81 ± 0.51 | 0.028 | − 0.48 ± 0.38△ | − 0.13 ± 0.17△ | 0.009 | − 0.48 ± 0.34△▲ | − 0.46 ± 0.33△▲ | 0.895 |
| nD-eye | − 1.35 ± 1.12 | − 0.73 ± 0.66 | 0.088 | − 0.65 ± 0.48△ | − 0.23 ± 0.17△ | 0.003 | − 0.50 ± 0.45△▲ | − 0.40 ± 0.39△ | 0.509 | |
| SE (D) | D-eye | − 11.42 ± 3.12 | − 7.34 ± 3.06 | 0.008 | − 0.07 ± 0.28△ | − 0.06 ± 0.27△* | 0.963 | − 0.57 ± 0.34△ | − 0.69 ± 0.67△▲* | 0.702 |
| nD-eye | − 12.18 ± 3.68 | − 8.91 ± 4.38 | 0.031 | − 0.49 ± 0.36△ | − 1.61 ± 0.96△* | < 0.001 | − 1.02 ± 0.70△▲ | − 2.18 ± 1.03△▲* | < 0.001 | |
| CDVA(Logmar) | D-eye | 0.05 ± 0.07 | − 0.03 ± 0.06 | 0.018 | − 0.06 ± 0.07△ | − 0.02 ± 0.06 | 0.018 | − 0.07 ± 0.10△▲ | − 0.02 ± 0.13 | 0.389 |
| nD-eye | 0.05 ± 0.09 | − 0.01 ± 0.10 | 0.184 | − 0.03 ± 0.07△ | − 0.01 ± 0.09 | 0.378 | − 0.01 ± 0.15▲ | 0.04 ± 0.14 | 0.335 | |
| ADD (D) | 0.71 ± 0.35 | 1.33 ± 0.17 | 0.017 | NA | NA | NA | 1.38 ± 0.22△ | 1.81 ± 0.71△ | 0.174 | |
| Safety indices | D-eye | NA | NA | NA | 1.30 ± 0.19 | 0.99 ± 0.05 | < 0.001 | 1.35 ± 0.30 | 1.00 ± 0.21 | 0.001 |
| nD-eye | 1.24 ± 0.24 | 1.04 ± 0.09 | 0.004 | 1.21 ± 0.27 | 0.96 ± 0.20 | 0.015 | ||||
| Efficacy indices | D-eye | NA | NA | NA | 1.29 ± 0.21* | 0.96 ± 0.11* | 0.003 | 0.86 ± 0.24 | 0.73 ± 0.33* | 0.286 |
| nD-eye | 1.07 ± 0.34* | 0.62 ± 0.30* | < 0.001 | 0.72 ± 0.37 | 0.30 ± 0.21* | 0.001 | ||||
D-eye, dominant eye; nD-eye, nondominant eye; UDVA, uncorrected distance visual acuity; ADD, presbyopic add power; SE, spherical equivalent; CDVA, corrected distance visual acuity. △ versus Preoperative, P < 0.05. ▲ versus the 1-month follow-up, P < 0.05. * dominant eye versus nondominant eye, P < 0.05.
Values with statistical significance are shown in bold.